Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 230

1.

MDR/XDR-TB management of patients and contacts: Challenges facing the new decade. The 2020 clinical update by the Global Tuberculosis Network.

Migliori GB, Tiberi S, Zumla A, Petersen E, Chakaya JM, Wejse C, Muñoz Torrico M, Duarte R, Alffenaar JW, Schaaf HS, Marais BJ, Cirillo DM, Alagna R, Rendon A, Pontali E, Piubello A, Figueroa J, Ferlazzo G, García-Basteiro A, Centis R, Visca D, D'Ambrosio L, Sotgiu G; members of the Global Tuberculosis Network.

Int J Infect Dis. 2020 Feb 4. pii: S1201-9712(20)30045-X. doi: 10.1016/j.ijid.2020.01.042. [Epub ahead of print]

2.

Precision and personalized medicine and anti-TB treatment: Is TDM feasible for programmatic use?

Alffenaar JC, Akkerman OW, Kim HY, Tiberi S, Migliori GB.

Int J Infect Dis. 2020 Jan 26. pii: S1201-9712(20)30043-6. doi: 10.1016/j.ijid.2020.01.041. [Epub ahead of print]

3.

Pharmacokinetic Modeling, Simulation, and Development of a Limited Sampling Strategy of Cycloserine in Patients with Multidrug-/Extensively Drug-Resistant Tuberculosis.

van der Galiën R, Boveneind-Vrubleuskaya NV, Peloquin C, Skrahina A, Touw DJ, Alffenaar JC.

Clin Pharmacokinet. 2020 Jan 25. doi: 10.1007/s40262-020-00860-8. [Epub ahead of print]

PMID:
31981103
4.

Therapeutic drug monitoring using saliva as matrix: an opportunity for linezolid, but challenge for moxifloxacin.

van den Elsen SHJ, Akkerman OW, Jongedijk EM, Wessels M, Ghimire S, van der Werf TS, Touw DJ, Bolhuis MS, Alffenaar JC.

Eur Respir J. 2020 Jan 24. pii: 1901903. doi: 10.1183/13993003.01903-2019. [Epub ahead of print] No abstract available.

PMID:
31980497
5.

Exploring failure of antimicrobial prophylaxis and pre-emptive therapy for transplant recipients: a systematic review.

Märtson AG, Bakker M, Blokzijl H, Verschuuren EAM, Berger SP, Span LFR, van der Werf TS, Alffenaar JC.

BMJ Open. 2020 Jan 7;10(1):e034940. doi: 10.1136/bmjopen-2019-034940.

6.

Evaluation of target attainment of oral posaconazole suspension in immunocompromised children.

Lai T, Alffenaar JW, Kesson A, Bandodkar S, Roberts JA.

J Antimicrob Chemother. 2020 Mar 1;75(3):726-729. doi: 10.1093/jac/dkz481.

PMID:
31855264
7.

Nontuberculosis mycobacteria infections: would there be pharmacodynamics without pharmacokinetics?

Kim HY, Sintchenko V, Alffenaar JW.

Eur Respir J. 2019 Nov 28;54(5). pii: 1901508. doi: 10.1183/13993003.01508-2019. Print 2019 Nov. No abstract available.

PMID:
31780456
8.

Should we worry about bedaquiline exposure in the treatment of multidrug-resistant and extensively drug-resistant tuberculosis?

Alffenaar JC, Akkerman OW, Tiberi S, Sotgiu G, Migliori GB; Global Tuberculosis Network Bedaquiline study group.

Eur Respir J. 2020 Feb 12;55(2). pii: 1901908. doi: 10.1183/13993003.01908-2019. Print 2020 Feb. No abstract available.

PMID:
31699843
9.

Continuous versus intermittent infusion of cefotaxime in critically ill patients: a randomized controlled trial comparing plasma concentrations.

Aardema H, Bult W, van Hateren K, Dieperink W, Touw DJ, Alffenaar JC, Zijlstra JG.

J Antimicrob Chemother. 2020 Feb 1;75(2):441-448. doi: 10.1093/jac/dkz463.

PMID:
31697336
10.

Therapeutic Drug Monitoring Can Improve Linezolid Dosing Regimens in Current Clinical Practice: A Review of Linezolid Pharmacokinetics and Pharmacodynamics.

Rao GG, Konicki R, Cattaneo D, Alffenaar JW, Marriott DJE, Neely M.

Ther Drug Monit. 2020 Feb;42(1):83-92. doi: 10.1097/FTD.0000000000000710.

PMID:
31652190
11.

Surveillance of adverse events in the treatment of drug-resistant tuberculosis: first global report.

Borisov S, Danila E, Maryandyshev A, Dalcolmo M, Miliauskas S, Kuksa L, Manga S, Skrahina A, Diktanas S, Codecasa LR, Aleksa A, Bruchfeld J, Koleva A, Piubello A, Udwadia ZF, Akkerman OW, Belilovski E, Bernal E, Boeree MJ, Cadiñanos Loidi J, Cai Q, Cebrian Gallardo JJ, Dara M, Davidavičienė E, Forsman LD, De Los Rios J, Denholm J, Drakšienė J, Duarte R, Elamin SE, Escobar Salinas N, Ferrarese M, Filippov A, Garcia A, García-García JM, Gaudiesiute I, Gavazova B, Gayoso R, Gomez Rosso R, Gruslys V, Gualano G, Hoefsloot W, Jonsson J, Khimova E, Kunst H, Laniado-Laborín R, Li Y, Magis-Escurra C, Manfrin V, Marchese V, Martínez Robles E, Matteelli A, Mazza-Stalder J, Moschos C, Muñoz-Torrico M, Mustafa Hamdan H, Nakčerienė B, Nicod L, Nieto Marcos M, Palmero DJ, Palmieri F, Papavasileiou A, Payen MC, Pontarelli A, Quirós S, Rendon A, Saderi L, Šmite A, Solovic I, Souleymane MB, Tadolini M, van den Boom M, Vescovo M, Viggiani P, Yedilbayev A, Zablockis R, Zhurkin D, Zignol M, Visca D, Spanevello A, Caminero JA, Alffenaar JW, Tiberi S, Centis R, D'Ambrosio L, Pontali E, Sotgiu G, Migliori GB.

Eur Respir J. 2019 Dec 19;54(6). pii: 1901522. doi: 10.1183/13993003.01522-2019. Print 2019 Dec.

PMID:
31601711
12.

Integrating pharmacokinetics and pharmacodynamics in operational research to End TB.

Alffenaar JC, Gumbo T, Dooley KE, Peloquin CA, McIlleron H, Zagorski A, Cirillo DM, Heysell SK, Silva DR, Migliori GB.

Clin Infect Dis. 2019 Sep 27. pii: ciz942. doi: 10.1093/cid/ciz942. [Epub ahead of print]

PMID:
31560376
13.

Nationwide analysis of treatment outcomes in children and adolescents routinely treated for tuberculosis in the Netherlands.

Gafar F, Van't Boveneind-Vrubleuskaya N, Akkerman OW, Wilffert B, Alffenaar JC.

Eur Respir J. 2019 Dec 12;54(6). pii: 1901402. doi: 10.1183/13993003.01402-2019. Print 2019 Dec.

PMID:
31515410
14.

Respiratory syncytial virus infection morbidity in the elderly; time for repurposing of ribavirin?

de Zwart AES, Riezebos-Brilman A, Kerstjens HAM, Verschuuren EAM, Alffenaar JC.

Clin Infect Dis. 2019 Aug 24. pii: ciz835. doi: 10.1093/cid/ciz835. [Epub ahead of print] No abstract available.

PMID:
31504299
15.

Treatment of multidrug-resistant tuberculosis using therapeutic drug monitoring: first experiences with sub-300 mg linezolid dosages using in-house made capsules.

Bolhuis MS, van der Werf TS, Kerstjens HAM, de Lange WCM, Alffenaar JC, Akkerman OW.

Eur Respir J. 2019 Dec 4;54(6). pii: 1900580. doi: 10.1183/13993003.00580-2019. Print 2019 Dec. No abstract available.

PMID:
31439686
16.

Performance of a web-based application measuring spot quality in dried blood spot sampling.

Veenhof H, Koster RA, Brinkman R, Senturk E, Bakker SJL, Berger SP, Akkerman OW, Touw DJ, Alffenaar JC.

Clin Chem Lab Med. 2019 Nov 26;57(12):1846-1853. doi: 10.1515/cclm-2019-0437.

PMID:
31373896
17.

Treatment outcomes of drug-resistant tuberculosis in the Netherlands, 2005-2015.

Pradipta IS, Van't Boveneind-Vrubleuskaya N, Akkerman OW, Alffenaar JC, Hak E.

Antimicrob Resist Infect Control. 2019 Jul 12;8:115. doi: 10.1186/s13756-019-0561-z. eCollection 2019.

18.

In vitro evaluation of an intravenous microdialysis catheter for therapeutic drug monitoring of gentamicin and vancomycin.

van der Mast JE, Nijsten MW, Alffenaar JC, Touw DJ, Bult W.

Pharmacol Res Perspect. 2019 Jun 26;7(4):e00483. doi: 10.1002/prp2.483. eCollection 2019 Aug.

19.

Management of patients with multidrug-resistant tuberculosis.

Lange C, Aarnoutse RE, Alffenaar JWC, Bothamley G, Brinkmann F, Costa J, Chesov D, van Crevel R, Dedicoat M, Dominguez J, Duarte R, Grobbel HP, Günther G, Guglielmetti L, Heyckendorf J, Kay AW, Kirakosyan O, Kirk O, Koczulla RA, Kudriashov GG, Kuksa L, van Leth F, Magis-Escurra C, Mandalakas AM, Molina-Moya B, Peloquin CA, Reimann M, Rumetshofer R, Schaaf HS, Schön T, Tiberi S, Valda J, Yablonskii PK, Dheda K.

Int J Tuberc Lung Dis. 2019 Jun 1;23(6):645-662. doi: 10.5588/ijtld.18.0622.

PMID:
31315696
20.

Repurposed oral ribavirin for respiratory virus infections requires pharmacokinetic-pharmacodynamics for dose optimization.

de Zwart AES, Riezebos-Brilman A, Kerstjens HAM, Verschuuren EAM, Alffenaar JC.

Clin Infect Dis. 2019 Jul 4. pii: ciz593. doi: 10.1093/cid/ciz593. [Epub ahead of print] No abstract available.

PMID:
31271195
21.

Official International Association for Therapeutic Drug Monitoring and Clinical Toxicology Guideline: Development and Validation of Dried Blood Spot-Based Methods for Therapeutic Drug Monitoring.

Capiau S, Veenhof H, Koster RA, Bergqvist Y, Boettcher M, Halmingh O, Keevil BG, Koch BCP, Linden R, Pistos C, Stolk LM, Touw DJ, Stove CP, Alffenaar JC.

Ther Drug Monit. 2019 Aug;41(4):409-430. doi: 10.1097/FTD.0000000000000643.

PMID:
31268966
22.

Quality Assessment of Dried Blood Spots from Patients With Tuberculosis from 4 Countries.

Zuur MA, Veenhof H, Aleksa A, Vanʼt Boveneind-Vrubleuskaya N, Darmawan E, Hasnain MG, Heysell SK, Jongedijk EM, Koster RA, Magis-Escurra C, Martinez N, Molinas G, Mondal D, Mulyani UA, Perwitasari DA, Tsivunchyk A, Touw DJ, Alffenaar JC.

Ther Drug Monit. 2019 Dec;41(6):714-718. doi: 10.1097/FTD.0000000000000659.

PMID:
31169760
23.

Posaconazole therapeutic drug monitoring in clinical practice and longitudinal analysis of the effect of routine laboratory measurements on posaconazole concentrations.

Märtson AG, Veringa A, van den Heuvel ER, Bakker M, Touw DJ, van der Werf TS, Span LFR, Alffenaar JC.

Mycoses. 2019 Aug;62(8):698-705. doi: 10.1111/myc.12948. Epub 2019 Jun 18.

24.
25.

Acquired Drug Resistance: Recognizing the Potential of Repurposed Drugs.

Alffenaar JC, Sintchenko V, Marais BJ.

Clin Infect Dis. 2019 Nov 13;69(11):2038-2039. doi: 10.1093/cid/ciz334. No abstract available.

PMID:
31125392
26.

Reduced moxifloxacin exposure in patients with tuberculosis and diabetes.

Dekkers BGJ, Bolhuis MS, Ter Beek L, de Lange WCM, van der Werf TS, Alffenaar JC, Akkerman OW.

Eur Respir J. 2019 Sep 5;54(3). pii: 1900373. doi: 10.1183/13993003.00373-2019. Print 2019 Sep. No abstract available.

PMID:
31048350
27.

Limited Sampling Strategies Using Linear Regression and the Bayesian Approach for Therapeutic Drug Monitoring of Moxifloxacin in Tuberculosis Patients.

van den Elsen SHJ, Sturkenboom MGG, Akkerman OW, Manika K, Kioumis IP, van der Werf TS, Johnson JL, Peloquin C, Touw DJ, Alffenaar JC.

Antimicrob Agents Chemother. 2019 Jun 24;63(7). pii: e00384-19. doi: 10.1128/AAC.00384-19. Print 2019 Jul.

28.

Optimal Sampling Strategies for Therapeutic Drug Monitoring of First-Line Tuberculosis Drugs in Patients with Tuberculosis.

Saktiawati AMI, Harkema M, Setyawan A, Subronto YW, Sumardi, Stienstra Y, Aarnoutse RE, Magis-Escurra C, Kosterink JGW, van der Werf TS, Alffenaar JC, Sturkenboom MGG.

Clin Pharmacokinet. 2019 Nov;58(11):1445-1454. doi: 10.1007/s40262-019-00763-3.

29.

Surveillance of adverse events in the treatment of drug-resistant tuberculosis: A global feasibility study.

Akkerman O, Aleksa A, Alffenaar JW, Al-Marzouqi NH, Arias-Guillén M, Belilovski E, Bernal E, Boeree MJ, Borisov SE, Bruchfeld J, Cadiñanos Loidi J, Cai Q, Caminero JA, Cebrian Gallardo JJ, Centis R, Codecasa LR, D'Ambrosio L, Dalcolmo M, Danila E, Dara M, Davidavičienė E, Davies Forsman L, De Los Rios Jefe J, Denholm J, Duarte R, Elamin SE, Ferrarese M, Filippov A, Ganatra S, Garcia A, García-García JM, Gayoso R, Giraldo Montoya AM, Gomez Rosso RG, Gualano G, Hoefsloot W, Ilievska-Poposka B, Jonsson J, Khimova E, Kuksa L, Kunst H, Laniado-Laborín R, Li Y, Magis-Escurra C, Manfrin V, Manga S, Marchese V, Martínez Robles E, Maryandyshev A, Matteelli A, Migliori GB, Mullerpattan JB, Munoz-Torrico M, Mustafa Hamdan H, Nieto Marcos M, Noordin NM, Palmero DJ, Palmieri F, Payen MC, Piubello A, Pontali E, Pontarelli A, Quirós S, Rendon A, Skrahina A, Šmite A, Solovic I, Sotgiu G, Souleymane MB, Spanevello A, Stošić M, Tadolini M, Tiberi S, Udwadia ZF, van den Boom M, Vescovo M, Viggiani P, Visca D, Zhurkin D, Zignol M; members of the International Study Group on new anti-tuberculosis drugs and adverse events monitoring.

Int J Infect Dis. 2019 Jun;83:72-76. doi: 10.1016/j.ijid.2019.03.036. Epub 2019 Apr 3.

30.

Relevance of the drug-drug interactions between lidocaine and the pharmacokinetic enhancers ritonavir and cobicistat.

Dekkers BGJ, Bierman WFW, Touw DJ, Alffenaar JC.

AIDS. 2019 May 1;33(6):1100-1102. doi: 10.1097/QAD.0000000000002162. No abstract available.

31.

Clinical application of a dried blood spot assay for sirolimus and everolimus in transplant patients.

Veenhof H, Koster RA, Alffenaar JC, van den Berg AP, de Groot MR, Verschuuren EAM, Berger SP, Bakker SJL, Touw DJ.

Clin Chem Lab Med. 2019 Nov 26;57(12):1854-1862. doi: 10.1515/cclm-2019-0053.

32.

Diabetes mellitus comorbidity in patients enrolled in tuberculosis drug efficacy trials around the world: A systematic review.

Lutfiana NC, van Boven JFM, Masoom Zubair MA, Pena MJ, Alffenaar JC.

Br J Clin Pharmacol. 2019 Jul;85(7):1407-1417. doi: 10.1111/bcp.13935. Epub 2019 May 17. Review.

33.

A volumetric absorptive microsampling LC-MS/MS method for five immunosuppressants and their hematocrit effects.

Koster RA, Niemeijer P, Veenhof H, Hateren KV, Alffenaar JC, Touw DJ.

Bioanalysis. 2019 Mar;11(6):495-508. doi: 10.4155/bio-2018-0312. Epub 2019 Mar 20.

PMID:
30892068
34.

Different Underlying Mechanism Might Explain the Absence of a Significant Difference in Area Under the Concentration-Time Curve of Linezolid for Different ABCB1 Genotypes.

Bolhuis MS, Akkerman OW, Sturkenboom MGG, de Lange WCM, van der Werf TS, Touw DJ, Alffenaar JC.

Ther Drug Monit. 2019 Apr;41(2):253-254. doi: 10.1097/FTD.0000000000000597. No abstract available.

PMID:
30883521
35.

Ganciclovir Therapeutic Drug Monitoring: A Case Series.

Märtson AG, Touw D, Damman K, Bakker M, Oude Lansink-Hartgring A, van der Werf T, Knoester M, Alffenaar JC.

Ther Drug Monit. 2019 Apr;41(2):107-110. doi: 10.1097/FTD.0000000000000598. Erratum in: Ther Drug Monit. 2019 Jun;41(3):408.

36.

Tuberculosis-Related Malnutrition: Public Health Implications.

Ter Beek L, Alffenaar JC, Bolhuis MS, van der Werf TS, Akkerman OW.

J Infect Dis. 2019 Jun 19;220(2):340-341. doi: 10.1093/infdis/jiz091. No abstract available.

PMID:
30835281
37.

Evaluation of Saliva as a Potential Alternative Sampling Matrix for Therapeutic Drug Monitoring of Levofloxacin in Patients with Multidrug-Resistant Tuberculosis.

Ghimire S, Maharjan B, Jongedijk EM, Kosterink JGW, Ghimire GR, Touw DJ, van der Werf TS, Shrestha B, Alffenaar JC.

Antimicrob Agents Chemother. 2019 Apr 25;63(5). pii: e02379-18. doi: 10.1128/AAC.02379-18. Print 2019 May.

38.

Standards for MIC testing that apply to the majority of bacterial pathogens should also be enforced for Mycobacterium tuberculosis complex.

Schön T, Matuschek E, Mohamed S, Utukuri M, Heysell S, Alffenaar JW, Shin S, Martinez E, Sintchenko V, Maurer FP, Keller PM, Kahlmeter G, Köser CU.

Clin Microbiol Infect. 2019 Apr;25(4):403-405. doi: 10.1016/j.cmi.2019.01.019. Epub 2019 Feb 14. No abstract available.

PMID:
30771527
39.

Levofloxacin pharmacokinetics, pharmacodynamics and outcome in multidrug-resistant tuberculosis patients.

Ghimire S, Maharjan B, Jongedijk EM, Kosterink JGW, Ghimire GR, Touw DJ, van der Werf TS, Shrestha B, Alffenaar JC.

Eur Respir J. 2019 Apr 18;53(4). pii: 1802107. doi: 10.1183/13993003.02107-2018. Print 2019 Apr. No abstract available.

PMID:
30655280
40.

The Role of Fluoroquinolones in the Treatment of Tuberculosis in 2019.

Pranger AD, van der Werf TS, Kosterink JGW, Alffenaar JWC.

Drugs. 2019 Feb;79(2):161-171. doi: 10.1007/s40265-018-1043-y. Review.

41.

Polymorphisms of NAT2, CYP2E1, GST, and HLA related to drug-induced liver injury in indonesian tuberculosis patients.

Perwitasari DA, Darmawan E, Mulyani UA, Vlies PV, Alffenaar JC, Atthobar J, Wilffert B.

Int J Mycobacteriol. 2018 Oct-Dec;7(4):380-386. doi: 10.4103/ijmy.ijmy_143_18.

42.

Comment on: The potential use of rifabutin for treatment of patients diagnosed with rifampicin-resistant tuberculosis.

Akkerman OW, Alffenaar JWC.

J Antimicrob Chemother. 2019 Mar 1;74(3):834. doi: 10.1093/jac/dky490. No abstract available.

PMID:
30508093
43.

Linezolid-based Regimens for Multidrug-resistant Tuberculosis (TB): A Systematic Review to Establish or Revise the Current Recommended Dose for TB Treatment.

Bolhuis MS, Akkerman OW, Sturkenboom MGG, Ghimire S, Srivastava S, Gumbo T, Alffenaar JC.

Clin Infect Dis. 2018 Nov 28;67(suppl_3):S327-S335. doi: 10.1093/cid/ciy625.

PMID:
30496467
44.

Amikacin Dosing for MDR Tuberculosis: A Systematic Review to Establish or Revise the Current Recommended Dose for Tuberculosis Treatment.

Sturkenboom MGG, Simbar N, Akkerman OW, Ghimire S, Bolhuis MS, Alffenaar JC.

Clin Infect Dis. 2018 Nov 28;67(suppl_3):S303-S307. doi: 10.1093/cid/ciy613.

PMID:
30496466
45.

d-Cycloserine Pharmacokinetics/Pharmacodynamics, Susceptibility, and Dosing Implications in Multidrug-resistant Tuberculosis: A Faustian Deal.

Deshpande D, Alffenaar JC, Köser CU, Dheda K, Chapagain ML, Simbar N, Schön T, Sturkenboom MGG, McIlleron H, Lee PS, Koeuth T, Mpagama SG, Banu S, Foongladda S, Ogarkov O, Pholwat S, Houpt ER, Heysell SK, Gumbo T.

Clin Infect Dis. 2018 Nov 28;67(suppl_3):S308-S316. doi: 10.1093/cid/ciy624.

46.

Pharmacokinetic/Pharmacodynamic Background and Methods and Scientific Evidence Base for Dosing of Second-line Tuberculosis Drugs.

Gumbo T, Alffenaar JC.

Clin Infect Dis. 2018 Nov 28;67(suppl_3):S267-S273. doi: 10.1093/cid/ciy608.

47.

Darunavir Population Pharmacokinetic Model Based on HIV Outpatient Data.

Daskapan A, Tran QTD, Cattaneo D, Gervasoni C, Resnati C, Stienstra Y, Bierman WFW, Kosterink JGW, van der Werf TS, Proost JH, Alffenaar JC, Touw DJ.

Ther Drug Monit. 2019 Feb;41(1):59-65. doi: 10.1097/FTD.0000000000000576.

48.

Regimen design and pharmacokinetic-pharmacodynamic science: lessons learned.

Alffenaar JC, Tiberi S, Migliori GB.

Lancet Infect Dis. 2019 Jan;19(1):3-4. doi: 10.1016/S1473-3099(18)30549-8. Epub 2018 Nov 23. No abstract available.

PMID:
30477962
49.

Role of Therapeutic Drug Monitoring in Treatment Optimization in Tuberculosis and Diabetes Mellitus Comorbidity.

Dekkers BGJ, Akkerman OW, Alffenaar JWC.

Antimicrob Agents Chemother. 2019 Jan 29;63(2). pii: e02074-18. doi: 10.1128/AAC.02074-18. Print 2019 Feb. No abstract available.

50.

Evaluation of Carbapenems for Treatment of Multi- and Extensively Drug-Resistant Mycobacterium tuberculosis.

van Rijn SP, Zuur MA, Anthony R, Wilffert B, van Altena R, Akkerman OW, de Lange WCM, van der Werf TS, Kosterink JGW, Alffenaar JC.

Antimicrob Agents Chemother. 2019 Jan 29;63(2). pii: e01489-18. doi: 10.1128/AAC.01489-18. Print 2019 Feb.

Supplemental Content

Loading ...
Support Center